Clinical-Pathologic Factors Associated with Hormone Receptor Expression Predict Prognosis in Breast Cancer
1 Department of Surgery, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, China
2 Department of Surgery, the Second Affiliated of Harbin Medical University, Harbin, China
3 Department of Surgery, Cancer Hospital Affiliated of Harbin Medical University, Harbin, China
*These authors contributed equally to this work
Cancer Genetics and Epigenetics, 2019, Vol. 7, No. 5 doi: 10.5376/cge.2019.07.0005
Received: 30 May, 2019 Accepted: 15 Jul., 2019 Published: 08 Aug., 2019
© 2019 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Song J., Zhang J.Y., Kang Y.J., and Zhang D.W., 2019, Clinical-Pathologic factors associated with hormone receptor expression predict prognosis in breast cancer, Cancer Genetics and Epigenetics, 7(5): 27-36 (doi: 10.5376/cge.2019.07.0005)
ER positive, PR negative tumors are an especial subtype of breast cancers with the character that having unfavorable outcome and tamoxifen resistance in spite of being ER positive. While there is little attention to the subgroup that within the majority of ER positive tumors there is a subtype with the ER positive, PR negative, whose outcome is as bad as the triple negative breast cancer (TNBC)or even worse. This review is mainly about the investigation of the clinicopathological features of the ER-positive and PR-negative subtype of the Luminal B-like breast cancer. The total amount of the patients is 320, they are hormone receptor positive breast cancer patients who were operated in 2006~2012 were included in the study. The percentage (79.1%) of expression of P53 protein among Luminal B subtype is higher than it was among Luminal A (20.9%).The index of Ki-67 was distinctly interrelated with the status of PR (P＜0.05), and it was more probably to have a higher Ki 67 index in Luminal B like breast cancers with PR positivity (53.4% VS 46.6%), PR negativity is associated with a dreadful outcome of Luminal B patients containing high risk of recurrence and short overall survival. P53 protein accumulation was correlated with prognosis of Luminal B breast cancers. In this article, we emphasize the role of PR HER-2 Ki67 and P53 in Luminal B breast cancer which have positive ER expression and negative PR expression. Our findings have revealed the expression of different biomarker have unique value to its sprognostic, and indicated that due to the high risk of relapse, the ER+/PR- Luminal-B tumors warrant further attention.
Breast cancer; Progesterone receptor; Prognostic
Cancer Genetics and Epigenetics
• Volume 7